Success Stories: Targeted Cancer Treatment Innovator Gains NIW Approval Through NAILG’s Advocacy
Client’s Testimonial:
“Thanks so much for informing me that the I-140 got approved. I really appreciate your help. I do not think that I can do it without you.”
On February 5th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoc Research Fellow in the Field of Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Postdoc Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: February 5th, 2025
Processing Time: 8 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (NAILG) is pleased to announce the NIW approval of a distinguished researcher in the field of biochemistry. With a focus on engineering immune cells and designing tumor-targeting therapies, the petitioner is developing next-generation treatment strategies to reduce cancer relapse and improve patient outcomes, an effort that addresses critical public health concerns in the United States.
The petitioner’s proposed endeavor centers on novel immunotherapy approaches, including the use of lentiviral systems to engineer immune cells and the development of conditionally dependent peptides that target tumors with high precision. These methods are aimed at enhancing the effectiveness of cancer treatments while minimizing side effects, offering hope to patients and families across the country affected by various forms of the disease.
At the time of filing, the petitioner published 9 peer-reviewed journal articles (2 as first author) and contributed 5 conference abstracts (4 first-authored). Her published work had received 411 citations, reflecting its impact on the biomedical research community. Her background and scientific output made a compelling case for her ability to advance this nationally significant line of inquiry.
Beyond her academic contributions, her work aligns closely with U.S. priorities in improving healthcare delivery and advancing innovative treatment options. The research not only addresses the biological complexity of cancer but also targets therapeutic gaps that continue to challenge current clinical approaches.
NAILG structured a robust and persuasive petition, highlighting the petitioner’s qualifications, the national importance of her work, and her capacity to contribute meaningfully to the U.S. biomedical landscape. We are proud to have played a role in helping bring this researcher closer to continuing her life-saving research on American soil.
We congratulate the petitioner on this important milestone and look forward to the continued impact of her research on cancer care innovation.

